A new market research report on
the Global Pneumonia Vaccine market has introduced by KD Market
Insights. The report is dedicated to in-depth industry analysis of the
global Pneumonia Vaccine market. The Global Pneumonia
Vaccine analysis is broken
down on different segmentation levels including Market By Vaccine Type, By Product Type, By Sector, By distribution
channel.
The global pneumonia vaccines market was
valued at $7,083 million in 2017 and is expected to reach $10,215 million by
2025, growing at a CAGR of 5% from
2018 to 2025. Pneumonia is a lung infection that occurs in one or both the
lungs caused by bacteria, viruses, or fungi; however, bacterial pneumonia is
the most common form occurring in adults.
Pneumonia results in inflammation in the air sacs (known as
alveoli) of the lungs, which results in filling the alveoli with fluid (pus
cells), thus causing breathing problems. Pneumococcal disease is common in
young children, but older adults are at greatest risk of serious pneumococcal
infections and even death.
Thus, Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines, PCV13 and PPSV23. The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the market growth. Moreover, development of protein-based combination pneumococcal vaccines is expected to provide lucrative opportunities for the expansion of this market.
Thus, Center for Disease Control and Prevention (CDC) recommends administration of two pneumococcal vaccines, PCV13 and PPSV23. The key factors that drive the growth of the global pneumonia vaccine market include increase in prevalence of pneumonia across the globe, rise in government focus on immunization programs for pneumonia, and introduction of novel pneumococcal vaccines such as PCV10. However, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines restrain the market growth. Moreover, development of protein-based combination pneumococcal vaccines is expected to provide lucrative opportunities for the expansion of this market.
The
global pneumonia vaccine
market is segmented based on type, product,
distribution channel, sector, and region. Based on type, the market is
bifurcated into pneumococcal conjugate vaccine (PCV) and pneumococcal
polysaccharide vaccine (PPV). Products covered in the study include Synflorix,
Prevnar 13, PPSV- 23, PCV 13-PIPELINE, V114-MERCK, PCV-20-PFIZER, and
PCV-10-SII. Based on distribution channel, the market is categorized into
distribution partner companies, non-governmental organizations (NGO), and
government authorities. Based on sector, the market is bifurcated into public
and private. Based on region, the market is analyzed across North America,
Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
-
The study provides an in-depth analysis of the market along with the current
trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Analysis by type helps understand the various types of pneumonia vaccines used by healthcare providers.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Analysis by type helps understand the various types of pneumonia vaccines used by healthcare providers.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Vaccine Type
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
By Product Type
- Prevnar 13
- Synflorix
- Pneumovax 23
- Prevnar 13
- Synflorix
- Pneumovax 23
By Sector
- Public
- Private
- Public
- Private
By distribution channel
- Distribution Partner Companies
- Non-governmental Organizations (NGO)
- Government Authorities
- Distribution Partner Companies
- Non-governmental Organizations (NGO)
- Government Authorities
By Country
- North America
- Europe
- Asia-Pacific
- LAMEA
- North America
- Europe
- Asia-Pacific
- LAMEA
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/pneumonia-vaccine-market-amr
Table of Content
CHAPTER 1: INTRODUCTION
1.1.
Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1.
Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1.
Key findings of the study
2.2. CXO perspective
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1.
Market definition and scope
3.2. Key findings
3.2. Key findings
3.2.1.
Top investment pockets
3.2.2. Top winning strategies, 2016–2018
3.2.3. Top strategies:
3.2.2. Top winning strategies, 2016–2018
3.2.3. Top strategies:
3.3.
Porters five forces analysis
3.3.1.
Bargaining power of suppliers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers
3.3.2. Threat of new entrants
3.3.3. Threat of substitutes
3.3.4. Competitive rivalry
3.3.5. Bargaining power among buyers
3.4.
Market share analysis, 2018
3.5. Market dynamics
3.5. Market dynamics
3.5.1.
Drivers
3.5.1.1.
Surge in prevalence of pneumonia across the globe
3.5.1.2. Rise in government focus on immunization programs for pneumonia
3.5.1.3. Increase in focus for novel pneumococcal vaccines
3.5.1.2. Rise in government focus on immunization programs for pneumonia
3.5.1.3. Increase in focus for novel pneumococcal vaccines
3.5.2.
Restraints
3.5.2.1.
Longer timelines required for pneumonia vaccine production
3.5.2.2. High cost associated with development of such vaccines
3.5.2.2. High cost associated with development of such vaccines
3.5.3.
Opportunity
3.5.3.1.
Development of protein-based combination pneumococcal vaccines
CHAPTER 4: PNEUMONIA VACCINES
MARKET, BY VACCINE TYPE
4.1.
Overview
4.1.1.
Market size and forecast
4.2.
Pneumococcal conjugate vaccine (PCV)
4.2.1.
Key market trends, growth factors and opportunities
4.2.2. Market size and forecast
4.2.2. Market size and forecast
4.3.
Pneumococcal polysaccharide vaccine (PPSV/PPV)
4.3.1.
Key market trends, growth factors and opportunities
4.3.2. Market size and forecast
4.3.2. Market size and forecast
CHAPTER 5: PNEUMONIA VACCINES
MARKET, BY PRODUCT TYPE
5.1.
Overview
5.1.1.
Market size and forecast
5.2.
Prevnar 13
5.2.1.
Key market trends, growth factors and opportunities
5.2.2. Market size and forecast
5.2.2. Market size and forecast
5.3.
Synflorix
5.3.1.
Key market trends, growth factors and opportunities
5.3.2. Market size and forecast
5.3.2. Market size and forecast
5.4.
Pneumovax23
5.4.1.
Key market trends, growth factors and opportunities
5.4.2. Market size and forecast
5.4.2. Market size and forecast
5.5.
Pipeline Products
CHAPTER 6: PNEUMONIA VACCINES MARKET,
BY SECTOR
6.1.
Overview
6.1.1.
Market size and forecast
6.2.
Public sector
6.2.1.
Market size and forecast
6.3.
Private sector
6.3.1.
Market size and forecast
CHAPTER 7: PNEUMONIA VACCINES
MARKET, BY DISTRIBUTION CHANNEL
7.1.
Overview
7.1.1.
Market size and forecast
7.2.
Distribution partner companies
7.2.1.
Key market trends, growth factors and opportunities
7.2.2. Market size and forecast
7.2.2. Market size and forecast
7.3.
Non-governmental Organizations (NGO)
7.3.1.
Key market trends, growth factors and opportunities
7.3.2. Market size and forecast
7.3.2. Market size and forecast
7.4.
Government Authorities
7.4.1.
Key market trends, growth factors and opportunities
7.4.2. Market size and forecast
7.4.2. Market size and forecast
CHAPTER 8: GLOBAL PNEUMONIA MARKET,
BY REGION
8.1.
Overview
8.1.1.
Market size and forecast
8.2.
North America
8.2.1.
Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast, by type
8.2.4. Market size and forecast, by product type
8.2.5. Market size and forecast, by distribution channel
8.2.6. Market size and forecast, by sector
8.2.7. Market size and forecast, by country
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast, by type
8.2.4. Market size and forecast, by product type
8.2.5. Market size and forecast, by distribution channel
8.2.6. Market size and forecast, by sector
8.2.7. Market size and forecast, by country
8.2.7.1.
The U.S. Pneumonia Vaccine Market
8.2.7.1.1.
Market Size and forecast, by type
8.2.7.1.2. Market Size and forecast, by product type
8.2.7.1.3. Market Size and forecast, by distribution channel
8.2.7.1.4. Market Size and forecast, by sector
8.2.7.1.2. Market Size and forecast, by product type
8.2.7.1.3. Market Size and forecast, by distribution channel
8.2.7.1.4. Market Size and forecast, by sector
8.2.7.2.
Canada Pneumonia Vaccine Market
8.2.7.2.1.
Market Size and forecast, by type
8.2.7.2.2. Market Size and forecast, by product type
8.2.7.2.3. Market Size and forecast, by distribution channel
8.2.7.2.4. Market Size and forecast, by sector
8.2.7.2.2. Market Size and forecast, by product type
8.2.7.2.3. Market Size and forecast, by distribution channel
8.2.7.2.4. Market Size and forecast, by sector
8.2.7.3.
Mexico Pneumonia Vaccine Market
8.2.7.3.1.
Market Size and forecast, by type
8.2.7.3.2. Market Size and forecast, by product type
8.2.7.3.3. Market Size and forecast, by distribution channel
8.2.7.3.4. Market Size and forecast, by sector
8.2.7.3.2. Market Size and forecast, by product type
8.2.7.3.3. Market Size and forecast, by distribution channel
8.2.7.3.4. Market Size and forecast, by sector
8.3.
Europe
8.3.1.
Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast, by type
8.3.4. Market size and forecast, by product type
8.3.5. Market size and forecast, by distribution channel
8.3.6. Market size and forecast, by sector
8.3.7. Market size and forecast, by country
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast, by type
8.3.4. Market size and forecast, by product type
8.3.5. Market size and forecast, by distribution channel
8.3.6. Market size and forecast, by sector
8.3.7. Market size and forecast, by country
Continue @...
About Us:
KD Market
Insights offers a
comprehensive database of syndicated research studies, customized reports, and
consulting services. These reports are created to help in making smart, instant
and crucial decisions based on extensive and in-depth quantitative information,
supported by extensive analysis and industry insights. Our dedicated in-house
team ensures the reports satisfy the requirement of the client. We aim at
providing value service to our clients. Our reports are backed by extensive
industry coverage and is made sure to give importance to the specific needs of
our clients. The main idea is to enable our clients to make an informed
decision, by keeping them and ourselves up to date with the latest trends in
the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
This is dummy text. It is not meant to be read. Accordingly, it is difficult to figure out when to end it. But then, this is dummy text. It is not meant to be read. Period.
ConversionConversion EmoticonEmoticon